We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00839696
Recruitment Status : Completed
First Posted : February 9, 2009
Last Update Posted : December 9, 2014
United States Department of Defense
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
Mammographic density is sensitive to estorgen exposure and constitutes a strong intermediate maker of breast cancer risk. We hypothesize that women with higher serum xenoestrogen levels will have greater mammographic density.

Condition or disease Phase
Breast Cancer Risk Phase 4

Study Type : Observational
Actual Enrollment : 270 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Study Start Date : July 2008
Primary Completion Date : June 2009
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Primary Outcome Measures :
  1. Characterize the distribution of total xenoestrogen burden and identify important source of xenoestrogen exposure among a clinic-based sample of postmenopausal women. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Evaluate the association of total xenoestorgen exposure with mammographic density. [ Time Frame: 1 year ]

Biospecimen Retention:   Samples Without DNA
Serum Xenoestrogen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects recruited from screening mammography population

Inclusion Criteria:

  • 55-70 years of age, Post menopausal

Exclusion Criteria:

  • If they have ever used hormone replacment therapy or have ever used Tamoxifen or Raloxifene, Diag. with breast cancer have had breast implants or have had a mastectomy/

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00839696

United States, Wisconsin
University of Wisconsin Hospital
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
United States Department of Defense
Principal Investigator: Amy Trentham Dietz, PhD Associate Professor- Population Health Sciences, UW School of Medicine and Public Health

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00839696     History of Changes
Other Study ID Numbers: CC07104
First Posted: February 9, 2009    Key Record Dates
Last Update Posted: December 9, 2014
Last Verified: December 2014

Keywords provided by University of Wisconsin, Madison:

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases